Streetbeat News

Regulatory

WDGJF

John Wood Group PLC shares fell sharply after announcing an independent review by Deloitte due to project write-offs.

Portfolio Pulse from

November 07, 2024 | 9:30 am

ZLDPF

Zealand Pharma plans to start a phase 2b trial for its obesity drug candidate, petrelintide, in Q4 2024.

Portfolio Pulse from

November 07, 2024 | 6:45 am

CVRX

CVRx's Barostim therapy is experiencing strong clinical success and revenue growth, bolstered by recent CMS reimbursement approvals. However, the company's path to profitability is challenged by rising SG&A costs and potential shareholder dilution.

Portfolio Pulse from

November 07, 2024 | 2:30 am

OUSA

The article discusses the potential impact of a new Trump administration implementing wide-ranging tariffs, which could have significant implications for the U.S. economy. Investors are advised to consider quality investing strategies to navigate these potential changes.

Portfolio Pulse from

November 06, 2024 | 11:45 pm

INTC

Donald Trump's potential second term as President could significantly impact Intel due to his policies favoring domestic US manufacturing.

Portfolio Pulse from

November 06, 2024 | 11:30 pm

GFS

GlobalFoundries and at least two other chipmakers are set to receive their final Chips and Science Act awards from the Biden administration, indicating progress in the award rollout process.

Portfolio Pulse from

November 06, 2024 | 11:30 pm

CPIX

Cumberland Pharmaceuticals has received FDA Orphan Drug and Rare Pediatric Disease designations for Ifetroban, a treatment for cardiomyopathy associated with Duchenne muscular dystrophy.

Portfolio Pulse from

November 06, 2024 | 10:30 pm

IBKR

Thomas Peterffy, founder and chairman of Interactive Brokers, discusses the potential impact of a Trump second term on the financial sector, suggesting a more favorable regulatory environment.

Portfolio Pulse from

November 06, 2024 | 10:30 pm